BRCA1/2突变患者子宫癌风险是否影响预防性子宫切除术决策:系统综述与荟萃分析
该系统综述与荟萃分析纳入8项研究、13,098例BRCA1/2突变患者,比较观察与预期子宫癌发生率。结果显示BRCA1/2突变患者子宫癌风险显著高于一般人群(SIR=2.22,95%CI 1.76-2.8,p<0.001),子宫浆液性乳头状癌风险尤其突出(SIR=17.97,95%CI 9.89-32.66,p<0.001)。作者认为USPC可能是BRCA1/2综合征组成部分,预防性双侧输卵管卵巢切除时是否同期行子宫切除应个体化决策。
要点
- BRCA1/2突变患者子宫癌总体风险显著高于一般人群(SIR=2.22)。
- 子宫浆液性乳头状癌风险显著升高(SIR=17.97),BRCA1和BRCA2突变分别分析亦升高。
- 降低风险双侧输卵管卵巢切除时是否同期子宫切除应个体化考虑。
核心结论
- BRCA1/2突变患者发生子宫癌尤其是子宫浆液性乳头状癌的风险显著高于一般人群,USPC可能是BRCA1/2综合征的组成部分。
- 在降低风险双侧输卵管卵巢切除时是否同期行子宫切除术应个体化决策。
研究设计与样本
- 系统综述与荟萃分析,按照PRISMA声明进行,方案在PROSPERO前瞻性注册(注册号CRD42020193496)。
- 数据库检索共识别4591条记录,最终纳入8项研究,合计13,098例BRCA1/2突变患者。
- 纳入标准为提供BRCA1/2突变患者子宫癌诊断率、并按已知疾病发病率比较观察与预期发生率的研究,结果以标准化发病比(SIR)衡量。
- 主要结局为任何子宫癌诊断,并针对子宫浆液性乳头状癌(USPC)及BRCA1、BRCA2突变分别进行亚组分析。
主要发现
- BRCA1/2突变患者子宫癌风险显著高于一般人群(SIR=2.22,95%CI 1.76-2.8,p<0.001)。
- BRCA1/2突变患者USPC发生率显著升高(SIR=17.97,95%CI 9.89-32.66,p<0.001)。
- BRCA1突变患者子宫癌风险显著升高(SIR=2.81,95%CI 2.09-3.79,p<0.001)。
- BRCA2突变患者子宫癌风险亦显著升高(SIR=1.75,95%CI 1.09-2.80,p<0.001)。
关键数值与推荐
- 子宫癌总体SIR=2.22(95%CI 1.76-2.8,p<0.001)。
- USPC的SIR=17.97(95%CI 9.89-32.66,p<0.001)。
- BRCA1突变子宫癌SIR=2.81(95%CI 2.09-3.79,p<0.001)。
- BRCA2突变子宫癌SIR=1.75(95%CI 1.09-2.80,p<0.001)。
临床怎么用
- 对BRCA1/2突变患者进行遗传咨询时,应告知其子宫癌尤其是USPC风险升高。
- 在降低风险双侧输卵管卵巢切除时是否同期行子宫切除术,应结合个体情况个体化决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study the possible association between uterine cancer and the BRCA1/2 associated cancer syndrome and discuss the implications of such an association on the clinical managment of patients with BRCA1/2 mutations. METHODS: A systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses statement. Study protocol was prospectively registered at PROSPERO International prospective register of systematic reviews (registration number CRD42020193496). Considered for inclusion were studies providing the diagnosis rate of uterine cancer in patients with BRCA1/2 mutations by comparing observed and expected rate according to a known disease incidence. The results were measured by standardized incidence ratio (SIR). The primary outcome was defined as any uterine cancer diagnosis and subgroup analyses were conducted for uterine serous papillary cancer (USPC) specifically and for BRCA1 and BRCA2 mutations separately. RESULTS: 4591 records were identified through database search; eight studies were finally included, comprising 13,098 patients with BRCA1/2 mutations. BRCA1/2 mutated patients were found to have a significantly higher risk for uterine cancer compared to the general population (SIR = 2.22, 95% CI 1.76-2.8, p < 0.001). A higher incidence of USPC was also found in patients with BRCA1/2 mutations (SIR = 17.97, 95% CI 9.89-32.66, p < 0.001), as well as in a separate analysis for BRCA1 (SIR = 2.81, 95% CI 2.09-3.79, p < 0.001) and BRCA2 (SIR = 1.75, 95% CI 1.09-2.80, p < 0.001) mutations. CONCLUSION: Patients who carry a BRCA1/2 mutation are at a significantly higher risk of developing uterine cancer, specifically USPC, supporting that USPC may be a component of the BRCA1/2 syndrome. The decision to perform concurrent hysterectomy at the time of the risk reduction bilateral salpingo -oophorectomy surgery should be considered individually.
引用
- Nahshon C, Segev Y, Gemer O, et al. Should the risk for uterine cancer influence decision making for prophylactic hysterectomy in BRCA1/2 mutated patients- a systematic review and meta-analysis. Gynecol Oncol. 2020. PMID: 33309051. doi:10.1016/j.ygyno.2020.11.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。